Gross Profit Analysis: Comparing Amgen Inc. and Alkermes plc

Amgen vs. Alkermes: A Decade of Gross Profit Trends

__timestampAlkermes plcAmgen Inc.
Wednesday, January 1, 201417091400015641000000
Thursday, January 1, 201514494200017435000000
Friday, January 1, 201622642400018829000000
Sunday, January 1, 201733573700018780000000
Monday, January 1, 201849244800019646000000
Tuesday, January 1, 201947772900019006000000
Wednesday, January 1, 202046585200019265000000
Friday, January 1, 202156983800019525000000
Saturday, January 1, 202289368700019917000000
Sunday, January 1, 2023141036800019775000000
Monday, January 1, 202420566000000
Loading chart...

Unleashing insights

Gross Profit Trends: Amgen Inc. vs. Alkermes plc

In the ever-evolving pharmaceutical industry, understanding financial performance is crucial. This analysis delves into the gross profit trends of two industry giants, Amgen Inc. and Alkermes plc, from 2014 to 2023. Over this decade, Amgen consistently outperformed Alkermes, with its gross profit peaking at nearly $20 billion in 2022, a 27% increase from 2014. In contrast, Alkermes showed a remarkable growth trajectory, with its gross profit surging by over 700%, reaching approximately $1.4 billion in 2023. This stark contrast highlights Amgen's established market dominance and Alkermes' rapid growth potential. The data underscores the importance of strategic financial planning and market positioning in the pharmaceutical sector. As we move forward, these trends offer valuable insights into the competitive landscape and future opportunities for both companies.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025